Navigation Links
INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:3/18/2009

dose we've explored in the clinic to date and the dose of R7128 is only one-half the dose currently being studied in the clinic, we look forward to presenting the results of subsequent higher dose cohorts of INFORM-1."

INFORM-1 Study Design

The following information regarding the INFORM-1 study is available on www.clinicaltrials.gov:

  • Patients in Cohort A are dosed in two groups, Group A and Group B. Patients in Group A receive 500mg BID of R7128 as monotherapy for three days followed by four days of combination therapy comprised of the same dose of R7128 plus 100mg q8h of ITMN-191. Patients in Group B receive 100mg q8h of ITMN-191 as monotherapy for three days followed by four days of combination therapy comprised of the same dose of ITMN-191 plus 500mg BID of R7128.
  • Patients in Cohort B receive the same doses of R7128 and ITMN-191 as patients in both groups of Cohort A, but for a full 14 days in combination. Cohort B is referred to as Group C in the EASL abstract.
  • Patients in Cohort C are dosed in two groups, Group D and Group E. Patients in Group D receive 1000 mg BID of R7128 and 100mg q8h of ITMN-191 for 14 days. Patients in Group E receive 500 mg BID of R7128 and 200 mg q8h of ITMN-191 for 14 days.
  • Patients in Cohort D are dosed in one Group (Group F) and receive 1000 mg BID of R7128 and 200 mg of ITMN-191 q8h for 14 days.

About EASL

The European Association for the Study of the Liver (EASL) is the leading European association in the field of liver research. EASL brings together clinicians and scientists interested in the liver, providing an outlet for networking and learning. The EASL Annual Meeting attracts more than 7,000 participants annually.

About InterMune

Inte
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. Arpida Interim Results for six Months to 30 June 2007
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
5. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
6. IsoTis Reports Interim Results of Vote for Integra Merger
7. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
9. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
10. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
11. VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... days of demostrating Wisconsin's breakthroughs in biotechnology, the Wisconsin ... a discussion of what the state must do to attract ... Wisconsin has made in research, but explained without capital they ... moderator of the panel and president of the Wisconsin ...
... acquire AccuImage Diagnostic Corp. to expand its ... announced on Wednesday. , ,Merge eFilm, the business name ... with the San Francisco-based company in first-quarter 2005. , ... includes three-dimensional visualization tools that can be used for ...
... Milwaukee Metavante Corp. said it ... , which makes software that handles bank transactions and ... Marshall & Isley Corp, said in October that ... the software company into a wholly owned subsidiary. The ...
Cached Biology Technology:Out-of-state VCs offer advice on biotech investments 2Out-of-state VCs offer advice on biotech investments 3
(Date:11/18/2014)... Nov. 18, 2014  The Secure Identity & ... today jointly announce the formation of The Airport ... its Identity and Biometric Entry and Exit ... received official support from BORDERPOL, the international non-profit ... and provide expertise regarding border security, traveler and ...
(Date:11/15/2014)... 13, 2014  While we may still be a few ... in "Star Trek" to gain instant access to all that ... with smartphones and tablets for monitoring and measuring our health ... This may seem a tad Orwellian to some, but a ... of these technological opportunities into their healthcare regime. ...
(Date:11/7/2014)... Debra Auguste, associate professor, biomedical engineering, in the ... of New York, have identified a molecule that ... the most aggressive forms of breast cancer. , ... mortality rate owing to aggressive proliferation and metastasis ... Professor Auguste,s team, discovered the overexpression of intercellular ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... to put a price tag on the natural world? A ... rise of a new concept ecosystem services to ... Nature. Academic Dr Marion Potschin, of the University,s Centre ... who have been investigating the ethical considerations of this new ...
... . , Biopesticides containing beneficial fungi are ... Department of Agriculture (USDA) scientists have shown a liquid ... "liquid culture fermentation," offers several benefits, including lower material ... fungi, including Isaria or Metarhizium , ...
... CALGARY Researchers in Calgary have launched the first gene therapy ... enzyme deficiency that can shorten the lifespan of people who have ... first remove a quantity of stem cells from a Fabry patient,s ... inserted into the stem cells using a specially engineered virus. During ...
Cached Biology News:Valuing nature is not enough 2New, cost-cutting approach to formulating pest-killing fungi 2Canada launches first gene therapy trial for Fabry disease 2Canada launches first gene therapy trial for Fabry disease 3
...
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
... l-[35S]in vitro cell labeling mix, ... *Aqueous solution stabilized with 0.1% ... pyridine 3,4-dicarboxylic acid. *Amino acid ... labeling containing l-[35S]Methionine and l-[35S]Cysteine. ...
...
Biology Products: